| abstract |
The present disclosure relates to the use of anti-platelet agents for the treatment of thrombosis and related conditions in a subject. The anti-platelet agent, preferably a phosphoinositide 3-kinase beta (ΡΙ3Κβ) inhibitor such as TGX221 or AZD6482, may be administered alone or in combination with a thrombolytic agent, preferably recombinant tissue plasminogen activator (rtPA), and/or an anticoagulant agent, preferably argatroban. |